Lilly To Offer Zepbound Single-Dose Vials To Self-Pay Consumers

The company is offering Zepbound in single-dose 2.5mg and 5mg vials, both to expand supply and access, especially for patients without coverage for the obesity drug. 

• Source: Shutterstock

Eli Lilly and Company is looking to boost supplies of its obesity drug Zepbound (tirzepatide) by offering single-dose vials of the drug through its self-pay channel, at a cost that it described as being at least 50% less than other incretin medicines for obesity.

The Indianapolis-based drug maker said 27 August that it would make 2.5mg and 5mg single-dose vials of Zepbound available for...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Strategy

Lupin Confident Of US Growth On Tariff Mitigation, Rides High On Tolvaptan

 
• By 

Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.

Sanofi’s Sarclisa Wins Another EU Multiple Myeloma Nod In Its Unequal Battle With J&J’s Darzalex

 

The French drugmaker's anti-CD38 antibody has racked up another approval in first-line multiple myeloma, but it marks a small victory while the company develops a subcutaneous version to help level the field with J&J’s Darzalex.

More Players, Better Pricing, Tough Equity Market: Royalty Deals Go Mainstream

 
• By 

Royalty deals are on track for another blowout year, but it’s not only because of a depressed biotech market. Large investment firms such as KKR are taking note.

50% Levy On India And Brazil, US Tariffs Leave Global Trade, Forecasts In Disarray

 
• By 

50% tariffs on US imports from India, a range on others, an uncertain outcome of Section 232 investigations of pharma and talk of BRICS tariffs are making forecasting for the pharma industry extremely difficult, Scrip finds in this infographic analysis

More from Business

S&E In Brief: Launch Updates And Political Headwinds

 

Madrigal and Syndax update investors on their key launches, while Merck KGaA weighs in on the possibility of direct-to-consumer sales in the US.

2030’s Top Therapies: Incretin Agonists Loom Large

 

Scrip looks at the therapies projected to lead global sales by 2030. These frontrunners not only reflect advances in innovation but also shifting priorities in chronic disease management.

Lupin Confident Of US Growth On Tariff Mitigation, Rides High On Tolvaptan

 
• By 

Lupin is hoping moves like intellectual property transfer for some products to the US will help mitigate the tariff impact even as it counts on growth from planned launches of GLP-1s and biosimilars while riding high on tolvaptan launched in Q1.